MET and lung cancer: Besides, both MS‐275 and GM‐protac could inhibit the expression of HER‐2, Axl, c‐Met, and NF‐κB, but G‐protac had a weaker effect on these proteins, indicating the necessary of HDAC and EGFR signaling pathway inhibition on osimertinib‐resistant lung cancer.